Anti nk1.1 antibody

Unless otherwise specified, 100,000 breast cancer cells were injected s.c. adjacent to the inguinal mammary fat pad of female WT, Rag1^KO, Batf3^KO, Ifnar1^KO, Sting^KO, Ticam1^KO Myd88^KO, Ccr5^KO Cxcr3^KO, Ifnar1^KO, and Cxcr3 ^KO mice on the C57BL/6 background. 500,000 D4M.3A.3 melanoma and melanoma-MT cells were injected subcutaneously into the flanks of DMBA3-4-immunized and naive mice on the C57BL/6 background. In the LLC tumor model, 1,000,000 LLC cells were injected s.c. into flanks of naive mice on the C57BL/6 background. For macrophage and T cell depletion, clodronate liposome (catalog no. PBS-02, Liposoma BV), anti-mouse CD4 antibody (catalog no. BE0003, Bio X Cell), and anti-mouse CD8β antibody (catalog no. BE0223, Bio X Cell) were i.p. injected once a week, respectively. For natural killer cell depletion, Ncr1^iCre, ROSA^DTR mice were treated with diphtheria toxin (catalog no. D0564, Sigma-Aldrich) as well as anti-NK1.1 antibody (catalog no. BE0036, Bio X Cell). For DC depletion, CD11c-DTR mice were treated with diphtheria toxin. Tumor growth was monitored daily and measured on regular intervals. When a tumor reached 2 cm in diameter or became ulcerated, it was deemed terminal. In the lung metastasis mouse model, 500,000 DMBA3-4 versus DMSO3-1 cells were i.v. injected into tail vein of WT mice on the C57BL/6 background.